Business Description
Basilea Pharmaceutica Ltd
ISIN : CH0011432447
Compare
Compare
Traded in other countries / regions
BSLN.SwitzerlandBSLNz.UKPK5.GermanyBPMUF.USA IPO Date
2004-03-25Description
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.52 | |||||
| Equity-to-Asset | 0.07 | |||||
| Debt-to-Equity | 11.33 | |||||
| Debt-to-EBITDA | 2.44 | |||||
| Interest Coverage | 5.74 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.91 | |||||
| Beneish M-Score | 0.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.3 | |||||
| 3-Year Book Growth Rate | 24.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.89 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.5 | |||||
| 9-Day RSI | 25.99 | |||||
| 14-Day RSI | 29.29 | |||||
| 6-1 Month Momentum % | -2.43 | |||||
| 12-1 Month Momentum % | 17.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | |||||
| Quick Ratio | 2.38 | |||||
| Cash Ratio | 1.31 | |||||
| Days Inventory | 461.42 | |||||
| Days Sales Outstanding | 58.23 | |||||
| Days Payable | 54.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | 8.69 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.76 | |||||
| Operating Margin % | 38.79 | |||||
| Net Margin % | 32.11 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 24.54 | |||||
| ROIC % | 45.54 | |||||
| ROC (Joel Greenblatt) % | 128.13 | |||||
| ROCE % | 52.39 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.17 | |||||
| Forward PE Ratio | 9.21 | |||||
| PE Ratio without NRI | 9.17 | |||||
| Price-to-Owner-Earnings | 1025 | |||||
| PS Ratio | 3.01 | |||||
| PB Ratio | 32.77 | |||||
| Price-to-Tangible-Book | 33.72 | |||||
| Price-to-Free-Cash-Flow | 19.99 | |||||
| Price-to-Operating-Cash-Flow | 18.99 | |||||
| EV-to-EBIT | 8.39 | |||||
| EV-to-Forward-EBIT | 14.46 | |||||
| EV-to-EBITDA | 8.22 | |||||
| EV-to-Forward-EBITDA | 8.63 | |||||
| EV-to-Revenue | 3.27 | |||||
| EV-to-Forward-Revenue | 3.36 | |||||
| EV-to-FCF | 20.91 | |||||
| Price-to-Median-PS-Value | 0.41 | |||||
| Price-to-Graham-Number | 3.7 | |||||
| Earnings Yield (Greenblatt) % | 11.91 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Basilea Pharmaceutica Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 175.023 | ||
| EPS (TTM) (CHF) | 4.47 | ||
| Beta | 0.76 | ||
| Volatility % | 33.85 | ||
| 14-Day RSI | 29.29 | ||
| 14-Day ATR (CHF) | 1.091534 | ||
| 20-Day SMA (CHF) | 44.125 | ||
| 12-1 Month Momentum % | 17.27 | ||
| 52-Week Range (CHF) | 39.85 - 55.4 | ||
| Shares Outstanding (Mil) | 11.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Basilea Pharmaceutica Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Basilea Pharmaceutica Ltd Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Basilea Pharmaceutica Ltd Frequently Asked Questions
What is Basilea Pharmaceutica Ltd(XSWX:BSLN)'s stock price today?
The current price of XSWX:BSLN is CHF40.80. The 52 week high of XSWX:BSLN is CHF55.40 and 52 week low is CHF39.85.
When is next earnings date of Basilea Pharmaceutica Ltd(XSWX:BSLN)?
The next earnings date of Basilea Pharmaceutica Ltd(XSWX:BSLN) is .
Does Basilea Pharmaceutica Ltd(XSWX:BSLN) pay dividends? If so, how much?
Basilea Pharmaceutica Ltd(XSWX:BSLN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers